Evidence map›Paper›PMID 31403629›Full record

ArticleJournal of visualized experiments : JoVE2019

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes.

Saahir Khan, Aarti Jain, Omid Taghavian, Rie Nakajima, Algis Jasinskas, Medalyn Supnet, Jiin Felgner, Jenny Davies, Rafael Ramiro de Assis, Sharon Jan and 6 more

Abstract readEvaluation StudyVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. The Squalene Oil-in-Water Nanoemulsion Vaccine Carrier AddaVax Potentiates TLR-Induced B-Cell Responses.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Saahir KhanDivision of Infectious Diseases, Department of Medicine, University of California Irvine Health.
Aarti JainVaccine Research and Development Center, Department of Physiology, University of California Irvine.
Omid TaghavianVaccine Research and Development Center, Department of Physiology, University of California Irvine.
Rie NakajimaVaccine Research and Development Center, Department of Physiology, University of California Irvine.
Algis JasinskasVaccine Research and Development Center, Department of Physiology, University of California Irvine.
Medalyn SupnetVaccine Research and Development Center, Department of Physiology, University of California Irvine.
Jiin FelgnerVaccine Research and Development Center, Department of Physiology, University of California Irvine.
Jenny DaviesVaccine Research and Development Center, Department of Physiology, University of California Irvine.
Rafael Ramiro de AssisVaccine Research and Development Center, Department of Physiology, University of California Irvine.
Sharon JanVaccine Research and Development Center, Department of Physiology, University of California Irvine.
Joshua ObieroVaccine Research and Development Center, Department of Physiology, University of California Irvine.
Erwin StrahsburgerVaccine Research and Development Center, Department of Physiology, University of California Irvine.
Egest J PoneVaccine Research and Development Center, Department of Physiology, University of California Irvine.
Li LiangVaccine Research and Development Center, Department of Physiology, University of California Irvine.
D Huw DaviesVaccine Research and Development Center, Department of Physiology, University of California Irvine.
Philip L FelgnerVaccine Research and Development Center, Department of Physiology, University of California Irvine; pfelgner@uci.edu.

Funding

University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
Institutional Career Development CoreKL2TR001416 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI CAIOZZO, VINCENT JAMES, DEMETRIOU, MICHAEL · 2015 to 2023
$5.6M
NCATS NIH HHS KL2 TR001416NCATS NIH HHS UL1 TR001414
6 · The paper itself

Abstract

The influenza virus remains a significant cause of mortality worldwide due to the limited effectiveness of currently available vaccines. A key challenge to the development of universal influenza vaccines is high antigenic diversity resulting from antigenic drift. Overcoming this challenge requires novel research tools to measure the breadth of serum antibodies directed against many virus strains across different antigenic subtypes. Here, we present a protocol for analyzing the breadth of serum antibodies against diverse influenza virus strains using a protein microarray of influenza antigens. This influenza antigen microarray is constructed by printing purified hemagglutinin and neuraminidase antigens onto a nitrocellulose-coated membrane using a microarray printer. Human sera are incubated on the microarray to bind antibodies against the influenza antigens. Quantum-dot-conjugated secondary antibodies are used to simultaneously detect IgG and IgA antibodies binding to each antigen on the microarray. Quantitative antibody binding is measured as fluorescence intensity using a portable imager. Representative results are shown to demonstrate assay reproducibility in measuring subtype-specific and cross-reactive influenza antibodies in human sera. Compared to traditional methods such as ELISA, the influenza antigen microarray provides a high throughput multiplexed approach capable of testing hundreds of sera for multiple antibody isotypes against hundreds of antigens in a short time frame, and thus has applications in sero-surveillance and vaccine development. A limitation is the inability to distinguish binding antibodies from neutralizing antibodies.

Indexed as

Antibodies, NeutralizingAntibodies, ViralAntigens, ViralCohort StudiesCross ReactionsEnzyme-Linked Immunosorbent AssayHemagglutinin Glycoproteins, Influenza VirusHumansInfluenza, HumanInfluenza VaccinesNeuraminidaseProspective StudiesProtein Array AnalysisReproducibility of ResultsViral ProteinsAntibodies, NeutralizingAntibodies, ViralAntigens, ViralHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesNA protein, influenza A virusNeuraminidaseViral Proteins

Identifiers

PMID31403629
PMCPMC11177630

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.